Jason Hulse Murray Sells 24,057 Shares of PACS Group (NYSE:PACS) Stock

PACS Group, Inc. (NYSE:PACS) CEO Jason Murray sold 24,057 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $43.49, for a total transaction of $1,046,238.93. Following the sale, the chief executive officer directly owned 54,579,624 shares of the company’s stock, valued at $2,373,667,847.76. The trade was a 0.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jason Hulse Murray also recently made the following trade(s):

• On Wednesday, September 9th, Jason Murray sold 4,758 shares of PACS Group stock. The stock was sold at an average price of $43.33, for a total transaction of $206,164.14.
• On Friday, September 4th, Jason Murray sold 23,072 shares of PACS Group stock. The stock was sold at an average price of $42.69, for a total transaction of $984,943.68.
• On Thursday, September 3rd, Jason Murray sold 20,173 shares of PACS Group stock. The shares were sold at an average price of $42.56, for a total transaction of $858,562.88.
• On Wednesday, September 2nd, Jason Murray sold 23,783 shares of PACS Group stock. The shares were sold at an average price of $42.94, for a total transaction of $1,021,242.02.
• On Tuesday, September 1st, Jason Murray sold 24,157 shares of PACS Group stock. The shares were sold at an average price of $42.39, for a total transaction of $1,024,015.23.
• On Friday, August 21st, Jason Murray sold 59,244 shares of PACS Group stock. The stock was sold at an average price of $43.90, for a total transaction of $2,600,811.60.
• On Thursday, August 20th, Jason Murray sold 91,306 shares of PACS Group stock. The stock was sold at an average price of $43.92, for a total value of $4,010,159.52.
• On Wednesday, August 19th, Jason Murray sold 84,717 shares of PACS Group stock. The shares were sold at an average price of $44.26, for a total value of $3,749,574.42.
• On Tuesday, August 18th, Jason Murray sold 66,797 shares of PACS Group stock. The shares were sold at an average price of $44.18, for a total value of $2,951,091.46.
• On Monday, August 17th, Jason Murray sold 84,602 shares of PACS Group stock. The shares were sold at an average price of $44.16, for a total value of $3,736,024.32.

PACS Group Stock Performance

Shares of PACS Group stock opened at $44.77 on Friday. The business’s 50 day moving average price is $44.74 and its 200 day moving average price is $39.05. The company has a market cap of $7.08 billion, a price-to-earnings ratio of 26.03, a PEG ratio of 1.39 and a beta of -0.13. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.91 and a current ratio of 0.91. PACS Group, Inc. has a one year low of $8.00 and a one year high of $49.49.

PACS Group (NYSE:PACS) last issued its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.09. PACS Group had a return on equity of 29.55% and a net margin of 4.85%.The company had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.41 billion. On average, research analysts predict that PACS Group, Inc. will post 2.13 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PACS shares. Zacks Research upgraded shares of PACS Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Weiss Ratings cut shares of PACS Group from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. raised their price target on shares of PACS Group from $47.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. UBS Group raised their price target on shares of PACS Group from $57.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Oppenheimer lifted their price target on shares of PACS Group from $48.00 to $57.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, PACS Group has a consensus rating of “Buy” and a consensus target price of $58.80.

Institutional Trading of PACS Group

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in PACS Group by 2.2% during the third quarter. Vanguard Group Inc. now owns 3,939,725 shares of the company’s stock worth $54,092,000 after buying an additional 85,183 shares during the period. Alyeska Investment Group L.P. raised its stake in shares of PACS Group by 159.5% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,250,007 shares of the company’s stock valued at $86,378,000 after acquiring an additional 1,382,984 shares during the period. California State Teachers Retirement System lifted its holdings in shares of PACS Group by 3,298.3% in the 2nd quarter. California State Teachers Retirement System now owns 1,917,094 shares of the company’s stock worth $81,745,000 after acquiring an additional 1,860,680 shares during the last quarter. Balyasny Asset Management L.P. lifted its holdings in shares of PACS Group by 67.3% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,356,240 shares of the company’s stock worth $18,621,000 after acquiring an additional 545,348 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of PACS Group by 19.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,350,551 shares of the company’s stock worth $18,543,000 after purchasing an additional 220,939 shares during the period.

PACS Group Company Profile

PACS Group, Inc is a U.S. healthcare services company that operates skilled nursing and post-acute care facilities. Its facilities provide short-term rehabilitation, long-term skilled nursing, nursing care, and related clinical services for patients recovering from illness, injury, surgery, or hospitalization.

The company’s broader care offerings may include assisted living, memory care, behavioral health, and other specialized post-acute services, depending on the facility and market.